Spectrum announces asset purchase and license for immuno-oncology platform

This article was originally published here

The deal includes an exclusive license for the intellectual property related to the FIT antibody-interferon fusion technology drug delivery platform originally developed by scientists at UCLA. The license

The post Spectrum announces asset purchase and license for immuno-oncology platform appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply